# Speaker notes / talking points

[Why] Celiac is driven in the gut; a local-acting binder avoids systemic risk but must survive proteases.
[Reformat] We hold the epitope fixed across a six-stage hardening path.
[Interface] Hotspots come from experimental and modeled complexes.
[Hardening] Protease sites drop by about half with the interface intact.
[Developability] Paratopes are clean; liabilities are flagged.
[Roster] Three leads with defined epitopes and anchor structures.
[Trade-off] Negative charge drives non-absorption; we watch solubility.
[Next] Express and assay gut-stability, then confirm binding.